Ticker brief
PRAX PRAXIS PRECISION MEDICINES I
Consumer, Non-cyclical · Biotechnology
last close
$252.96
1 day
-2.3%
14 days
-2.7%
mkt cap
$8.9B
signals 14d
28
authors 14d
4
crowd 14d
+0.7σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 96% rich · 86 pctile own 1y | IV/HV 1.81× |
| Skew — 25Δ RR 30d | +0.005 81 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | -0.27 thin | 5-session Δ -0.19 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2025-12-08 (z=2.4) |
| Next earnings | 2026-11-09 (proj) | in 14d |
| CSP screen | rank #32 · $226.3 strike · 1.56% prem | on the CSP screen (2026-10-23) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-16 · now +0.60 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Biotech2k1 | A | +1.11 | 23 | +0.64 |
| @Quantumup1 | C | +0.10 | 3 | +0.32 |
| @MitchMartan98 | C | -3.79 | 1 | +0.40 |
| @BioStocks | C | -1.77 | 1 | +0.40 |
Recent signals28of 28 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @Biotech2k1 | +0.55 | The author identifies high-quality biotech names trading at substantial discounts from their highs. | +4.6% | tweet ↗ |
| 2026-10-16 | @Biotech2k1 | +0.65 | The author presents a researched ranking of core biotech holdings, led by INSM. | +4.6% | tweet ↗ |
| 2026-10-15 | @Quantumup1 | +0.40 | JPMorgan rated Praxis Overweight with a $700 target and placed it on a positive catalyst watch list. | +1.9% | tweet ↗ |
| 2026-10-15 | @Quantumup1 | +0.40 | UBS initiated Praxis at Buy with a $706 target ahead of a January 2027 FDA decision. | +1.9% | tweet ↗ |
| 2026-10-15 | @Biotech2k1 | +0.70 | Identifies a basket of biotech names viewed as mispriced excellence. | +1.9% | tweet ↗ |
| 2026-10-15 | @BioStocks | +0.40 | UBS initiated PRAX with a Buy rating and $706 target. | +1.9% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | +0.70 | Names a ranked basket of top biotech ideas based on strong fundamentals. | +4.0% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | +0.65 | Reports additional purchases in three biotech positions. | +4.0% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | +0.75 | Discloses 45% biotech weight, a 50% threshold and six core or potential holdings. | +4.0% | tweet ↗ |
| 2026-10-12 | @Biotech2k1 | +0.55 | Discloses biotech buying, 44.35% weighting and preferred value names. | +0.6% | tweet ↗ |
| 2026-10-12 | @Biotech2k1 | +0.40 | Explicitly ranks five biotech names by preference and approved/pending assets. | +0.6% | tweet ↗ |
| 2026-10-10 | @Biotech2k1 | +0.70 | Detailed portfolio letter discloses biotech holdings, sizing views, risks, and preferred entry levels. | -2.7% | tweet ↗ |
| 2026-10-09 | @Biotech2k1 | +0.65 | Bought half a LABD position at $7.50; bids the other half at $7 while long value biotech. — Explicit staged LABD entry hedges long positions in selected value-biotech names. | -2.7% | tweet ↗ |
| 2026-10-08 | @Biotech2k1 | +0.55 | Keep strongest biotech holdings and sell MDGL and other weak names into a rally. — Portfolio review gives explicit forward keep/sell plans backed by pipeline fundamentals. | -4.0% | tweet ↗ |
| 2026-10-08 | @Biotech2k1 | +0.60 | Author reports adding PRAX near 263.16. | -4.0% | tweet ↗ |
| 2026-10-08 | @Biotech2k1 | +0.75 | Discloses 42.5% biotech allocation and identifies preferred holdings and valuation views. | -4.0% | tweet ↗ |
| 2026-10-08 | @Biotech2k1 | +0.75 | Long-form bullish thesis cites management, pipeline, revenue potential, cash and no debt. | -4.0% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.75 | Cites three drugs, two upcoming PDUFAs, greater upside and cheaper valuation. | -9.0% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.65 | Discloses PRAX exposure through its epilepsy franchise and views it favorably. | -9.0% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.70 | Identifies INSM, BBIO, PRAX and PTGX as the author's four core biotech holdings. | -9.0% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.85 | Expects approvals to elevate PRAX to a top-three position and says it trades at 30% of real value. | -9.0% | tweet ↗ |
| 2026-10-07 | @Quantumup1 | +0.15 | Anticipates future UBS analyst coverage of three biotech stocks. | -9.0% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.50 | Outlines a hypothetical biotech allocation and cash plan for a severe correction. | -9.0% | tweet ↗ |
| 2026-10-06 | @MitchMartan98 | +0.40 | Creates a biotech watchlist of quality names after sharp declines. | -9.7% | tweet ↗ |
| 2026-10-06 | @Biotech2k1 | +0.60 | Discloses buying numerous biotech positions during a sharp sector decline. | -9.7% | tweet ↗ |
| 2026-10-06 | @Biotech2k1 | +0.60 | Load up on PTGX after a sufficient crash and PRAX after two approvals. — States conditional future accumulation plans for PTGX and PRAX. | -9.7% | tweet ↗ |
| 2026-10-06 | @Biotech2k1 | +0.45 | Calls four named biotech stocks cheap. | -9.7% | tweet ↗ |
| 2026-10-04 | @Biotech2k1 | +0.60 | Names four biotech stocks as the author's top value opportunities. | -14.4% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.